Review: Approaches to develop PLGA based in situ gelling system with low initial burst

Pakistan Journal of Pharmaceutical Sciences

Volumn 28, Issue 2, 2015, Pages 657-665

  Ahmed, Tarek ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

Drug delivery; In situ gelling system; Initial burst; PLGA

Indexed keywords

1 METHYL 2 PYRROLIDINONE; 2 PYRROLIDINONE; ACETIC ACID ETHYL ESTER; BENZYL BENZOATE; CITRIC ACID TRIETHYL ESTER; DIMETHYL SULFOXIDE; HALOPERIDOL; METOCLOPRAMIDE; POLYGLACTIN; TRIACETIN; GEL; LACTIC ACID; PLASTICIZER; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SURFACTANT;

BIOCOMPATIBILITY; DRUG RELEASE; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; PROTEIN QUATERNARY STRUCTURE; REVIEW; SCANNING ELECTRON MICROSCOPY; TISSUE ENGINEERING; VISCOSITY; CHEMISTRY; DRUG DELIVERY SYSTEM; GEL; SOLUBILITY;

DRUG DELIVERY SYSTEMS; GELS; LACTIC ACID; MOLECULAR WEIGHT; PLASTICIZERS; POLYGLYCOLIC ACID; SOLUBILITY; SURFACE-ACTIVE AGENTS; VISCOSITY;

EID: 84925004514     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Ahmed TA, Ibrahim HM, Ibrahim F, Samy AM, Kaseem A, Nutan MT and Hussain MD (2012). Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol. J. Pharm. Sci., 101(10): 3753-3762.
2. Arshady R (1991). Preparation of biodegradable microspheres and microcapsules: 2. Polylactides and related polyesters. J. Control Rel., 17: 1-22.
3. Banu S. Zolnik and Diane J. Burgess (2008). Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. Journal of Controlled Release, 127: 137-145.
4. Bezwada RS (1995). Liquid copolymers of epsiloncaprolactone and lactide, US Pat. 5 442 033.
5. Bodmer D, Kissel T and Traechslin E (1992). Factors influencing the release of peptides and proteins from biodegradable parenteral depot systems. J. Control Release, 21: 129-138.
6. Brodbeck KJ, Pushpala S and Mchugh AJ (1999). Sustained release of human growth hormone from PLGA solution depots. Pharm. Res., 16: 1825-1829.
7. Brodbeck KJ, Pushpala S and McHugh AJ (1999). Sustained release of human growth hormone from PLGA solution depots. Pharm. Res., 16: 1825-1829.
8. Chandrashekar BL, Zhou M, Jarr EM and Dunn RL (2000). Controlled release liquid delivery compositions with low initial drug burst, US Pat. 6: 143 314.
9. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R and Tyler RC (2002). A clinical study of 22.5 mg La- 2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer, J. Urol., 168(3): 1199-1203.
10. Cohen S, Alonso MJ and Langer R (1994). Novel approaches to controlled release antigen delivery. Int. J. Technol. Assessment Health Care, 10(1): 121-30.
11. Deadman CM, Kellaway IW, Yasin M, Dickinson PA and Murdan S (2007). An investigation into the influence of drug lipophilicity on the in vivo absorption profiles from subcutaneous microspheres and in situ forming depots. J. Control Release, 122(1): 79-85.
12. Desai KG, Mallery SR and Schwendeman SP (2008). Effect of formulation parameters on 2- methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants. Eur. J. Pharm. Biopharm., 70(1): 187-98.
13. Desai KGH, Olsen KF, Mallery SR, Stoner GD and Schwendeman SP (2010). Formulation and in vitro-in vivo evaluation of black raspberry extract-loaded PLGA/PLA injectable millicylindrical implants for sustained delivery of chemopreventive anthocyanins. Pharm. Res., 27: 628-642.
14. Dhawan S, Kapil R and Kapoor DN (2011) Development and evaluation of in situ gel-forming system for sustained delivery of insulin. J. Biomater. Appl., 25: 699-720.
15. Dittgen M, Fricke S, Gerecke H, Möller IP, Völkel C. Injection Implant, PCT/DE1997/002903[WO/1998/030245], 1998, Germany.
16. Dong WY, Körber M, López Esguerra V and Bodmeier R (2006). Stability of poly (D, L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J. Control. Release, 115: 158-167.
17. Dunn RL, Garrett JS, Ravivarapu H and Chandrashekar BL (2003). Polymeric delivery formulations of leuprolide with improved efficacy. US Patent, 6: 565-874.
18. Dunn RL, Tipton AJ, Southard GL and Rogers JA (1997). Biodegradable Polymer Composition, US Patent [5599552].
19. Elias-Al-Mamun M, Khan HA, Dewan I and Jalil RU (2009). In vitro study on tamsulosin release kinetics from biodegradable PLGA in situ implants. Pak. J. Pharm. Sci., 22(4): 360-367.
20. Eliaz R and Kost J (2000). Characterization of a polymeric PLGA-injectable implant delivery system for the controlled release of proteins, J. Biomed. Mater. Res., 50: 388-396.
21. Feng L, Qi XR, Zhou XJ, Maitani Y, Wang SC, Jiang Y and Nagai T (2006). Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release, 112: 35-42.
22. Fredenberg S, Wahlgren M, Reslow M and Axelsson A (2011). The mechanisms of drug release in poly (lacticco- glycolic acid)-based drug delivery systems. Int. J. Pharm., 415(1-2): 34-52.
23. Graham PD, Brodbeck KJ and McHugh AJ (1999). Phase inversion dynamics of PLGA solutions related to drug delivery, J. Control. Release, 58: 233-245.
24. Gutowska A, Jeong B and Jasionowski M (2001). Injectable gels for tissue engineering, Anat. Rec., 263: 342-349.
25. Hatefi A and Amsden B (2002). Biodegradable injectable in situ forming drug delivery systems, J. Control Release, 80: 9-28.
26. Houchin ML and Topp EM (2009). Physical properties of PLGA films during polymer degradation. J. Appl. Polym. Sci., 114: 2848-2854.
27. Huang X and Brazel ChS (2003). Analysis of burst release of proxyphylline from poly (vinylalcohol) hydrogels. Chem. Eng. Comm., 190: 519-532.
28. Ibrahim HM, Ahmed TA, Hussain MD, Rahman Z, Samy AM, Kaseem AA and Nutan MT (2014). Development of meloxicam in situ implants formulation by quality by design principle. Drug Dev. Ind. Pharm., 40(1):66-7.
29. Jain RA (2000). The manufacturing techniques of various drug loaded biodegradable poly (lactide-co-glycolide) (PLGA) devices. Biomaterials, 21: 2475-2490.
30. Jain RA, Rhodes CT, Railkar AM, Malick AW and Shah NH (2000). Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres:Effect of various formulation variables. Eur. J. Pharm. Biopharm., 50(2): 257-262.
31. Jalil R and Nixon JR (1990). Biodegradable poly (lactic acid) and poly (lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties. J. Microencapsulation, 7: 297-325.
32. Jeong B, Bae YH and Kim SW (2000). Drug release from biodegradable injectable thermo sensitive hydrogel of PEG-PLGA-PEG triblock copolymers. J. Control Release, 63: 155-163.
33. Jeong B, Bae YH and Kim SW (2000). In-situ gelation of PEG-PLGA-PEG triblock copolymer aqueous solutions and degradation thereof, J. Biomed. Mater. Res., 50: 171-177.
34. Jiang W, Gupta RK, Deshpande MC and Schwendeman SP (2005). Biodegradable poly (lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev., 57: 391-410.
35. Joo MK, Park MH, Choi BG and Jeong B (2009). Reverse thermogelling biodegradable polymer aqueous solutions, J. Mater. Chem., 19: 5891-5905.
36. Kang F and Singh J (2005). In vitro release of insulin and biocompatibility of in situ forming gel systems. Int. J. Pharm., 304: 83-90.
37. Kempe S and Mäder K (2012). In situ forming implants an attractive formulation principle for parenteral depot formulations. J. Control. Release, 161: 668-679.
38. Kishida A, Murakami K, Goto H, Akashi M, Kubita H and Endo T (1998). Polymer drugs and polymeric drugs. X. Slow release of 5-fluorouracil from biodegradable poly (g-glutamic acid) and its benzyl ester matrices. J. Bioact. Compat. Polym., 13: 270-278.
39. Kitchell JP and Wise DL (1985). Poly (lactic/glycolic acid) biodegradable drug-polymermatrix systems. Methods Enzymol., 112: 436-448.
40. Klose D, Siepmann F, Elkharraz K and Siepmann J (2008). PLGA-based drug delivery systems: importance of the type of drug and device geometry. Int. J. Pharm., 354: 95-103.
41. Ko DY, Shinde UP, Yeon B and Jeong B (2013). Recent progress of in situ formed gels for biomedical applications. Progress in Polymer Science, 38: 672- 701.
42. Kranz H and Bodmeier R (2007). A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int. J. Pharm., 332: 107-114.
43. Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W and Bodmeier R (2001). Myotoxicity studies of injectable biodegradable in situ forming drug delivery systems. Int. J. Pharm., 212: 11-18.
44. Kranz H., Bodmeier R (2008). Structure formation and characterization of injectable drug loaded biodegradable devices: In situ implants versus in situ microparticles. Eur. J. Pharm. Sci., 3(4): 164-172.
45. Lambert WJ, Peck KD (1995). Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the controlled release of proteins, J. Control Release, 33: 189-195.
46. Lewis DH (1990). Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M, Langer R, editors. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker., pp.1-41.
47. Lu S and Anseth KS (1998). Modeling and optimization of drug release from laminated polymer matrix devices. AIChE J., 44: 1689-1696.
48. Madan M, Lewis S and Baig JA (2009). Biodegradable injectable implant systems for sustained delivery using poly (lactide-co-glycolide) copolymers. International Journal of Pharmacy and Pharmaceutical Sciences, 1(1): 103-107.
49. Mallapragada SK, Peppas NA and Colombo P (1997). Crystal dissolution controlled release systems. II. Metronidazole release from semicrystalline poly (vinyl alcohol) systems. J. Biomed. Mater. Res., 36: 125-130.
50. McHugh A (2005). The role of polymer membrane formation in sustained release drug delivery systems. J. Control. Release, 109: 211-221.
51. Oh SH and Lee JH (2007). Fabrication and characterization of hydrophilized porous PLGA nerve guide conduits by a modified immersion precipitation method. J. Biomed. Mater. Res., 80: 530-538.
52. Paavola A, Yliruusi J and Rosenberg P (1998). Controlled release and dura mater permeability of lidocaine and ibuprofen from injectable poloxamer-based gels, J. Control Release, 52(1-2): 169-178.
53. Packhaeuser CB, Schnieders J, Oster CG and Kissel T (2004). In situ forming parenteral drug delivery systems: An overview, Eur. J. Pharm. Biopharm., 58: 445-455.
54. Patel RB, Carlson A, Solorio L and Exner AA (2010). Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems. J. Biomed. Mater Res. A., 94(2): 476-484.
55. Pekarek KJ, Jacob JS and Mathiowitz E (1994). Doublewalled microspheres for drug delivery. Mater. Res. Soc. Symp. Proc., 331: 97-101.
56. Ravivarapu HB, Moyer KL and Dunn RL (2000). Sustained activity and release of leuprolide acetate from an in situ forming polymeric implant. AAPS Pharm. Sci. Tech., 1(1): 1-8.
57. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC and Dunn RL (1999). Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys, J. Biomed. Mater. Res., 45: 231-239.
58. Sartor OE (2013). Eligard: Leuprolide acetate in a novel sustained-release delivery system. Urology, 61(2 Suppl 1): 25-31.
59. Shah NH, Railkar AS, Chen FC, Tarantino R, Kumar S, Murjani M, Palmer D, Infeld MH and Malick AW (1993). A biodegradable injectable implant for delivering micro and macromolecules using poly (lactic-co-glycolic) acid (PLGA) copolymers. J.Control Release, 27: 139-147.
60. Sharma G, Italia JL, Sonaje K, Tikoo K and Ravi Kumar MNV (2007). Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: Evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats. J. Control. Release, 118: 27-37.
61. Shively ML, Coonts BA, Renner WD, Southard JL and Bennet AT (1995). Physicochemical characterization of polymeric injectable implant delivery system. J. Control Release, 33: 237-243.
62. Siegel RA and Firestone BA (1988). PH-dependent equilibrium swelling properties of hydrophobic polyelectrolyte copoly-polymer gels. Macromolecules, 21: 3254-3259.
63. Strickley RG (2004). Solubilizing excipients in oral and injectable formulations. Pharm. Res., 21: 201-230.
64. Tan LP, Venkatraman SS, Sung PF and Wang XT (2004). Effect of plasticization on heparin release from biodegradable matrices. Int. J. Pharm., 283: 89-96.
65. Tanaka T (1980). Phase transitions in ionic gels. Phys. Rev. Lett., 45: 1636-1639.
66. Tang Y and Singh J (2008). Controlled delivery of aspirin: Effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems. International Journal of Pharmaceutics, 357: 119-125.
67. Tice TR and Cowsar DR (1984). Biodegradable controlled-release parenteral systems. Pharm. Technol., 11: 26-35.
68. Tice TR and Tabibi ES (1991). Parenteral drug delivery: Injectables. In: Kydonieus A, editor. Treatise on controlled drug delivery: Fundamentals optimization, applications. New York: Marcel Dekker. pp. 315-39.
69. Wang L, Venkatraman S and Kleiner L (2004). Drug release from injectable depots: Two different in vitro mechanisms. J. Control Release, 99: 207-216.
70. Wang X, Sui S, Yan Y and Zhang R (2010). Design and fabrication of PLGA sandwiched cell/fibrin constructs for complex organ regeneration. J. Bioactive Compatible Polym., 25: 229-240.
71. Wu XS (1995). Synthesis and properties of biodegradable lactic/glycolic acid polymers. In: Wise et al., editors. Encyclopedic handbook of Biomaterials and Bioengineering. New York: Marcel Dekker. pp. 1015- 1054.
72. Yeh MK, Davis SS and Coombes AG (1996). Improving protein delivery from microparticles using blends of poly (D, L lactide-co-glycolide) and poly (ethylene oxide)-poly (propylene oxide) copolymers. Pharm. Res., 13(11): 1693-1698.